Strategic Wealth Advisors Group LLC grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 3.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,469 shares of the medical research company’s stock after buying an additional 644 shares during the quarter. Strategic Wealth Advisors Group LLC’s holdings in Amgen were worth $3,568,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the stock. Gifford Fong Associates increased its position in shares of Amgen by 25.3% during the second quarter. Gifford Fong Associates now owns 67,671 shares of the medical research company’s stock worth $12,470,000 after acquiring an additional 13,671 shares during the period. Bray Capital Advisors increased its position in shares of Amgen by 11.6% during the second quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after acquiring an additional 2,045 shares during the period. CHICAGO TRUST Co NA increased its position in shares of Amgen by 2.8% during the second quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after acquiring an additional 100 shares during the period. Private Advisor Group LLC increased its position in shares of Amgen by 4.0% during the second quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock worth $7,093,000 after acquiring an additional 1,494 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Amgen during the second quarter worth $15,515,000. Hedge funds and other institutional investors own 76.33% of the company’s stock.
Shares of AMGN stock traded up $2.13 during mid-day trading on Friday, hitting $220.12. 103,869 shares of the stock were exchanged, compared to its average volume of 2,218,300. The stock’s fifty day simple moving average is $202.27 and its two-hundred day simple moving average is $188.68. The stock has a market capitalization of $127.80 billion, a price-to-earnings ratio of 15.28, a P/E/G ratio of 2.21 and a beta of 1.09. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $219.84. The company has a debt-to-equity ratio of 2.54, a quick ratio of 2.59 and a current ratio of 2.89.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.13. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.69 earnings per share. On average, research analysts expect that Amgen, Inc. will post 14.44 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.63%. Amgen’s dividend payout ratio (DPR) is 40.28%.
AMGN has been the topic of a number of recent research reports. Bank of America initiated coverage on Amgen in a research report on Wednesday, October 16th. They set a “neutral” rating and a $215.00 price objective on the stock. Citigroup reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 12th. BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a report on Monday, September 30th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $219.56.
In related news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total value of $413,400.00. Following the completion of the sale, the director now owns 16,336 shares in the company, valued at $3,376,651.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the sale, the director now owns 5,413 shares of the company’s stock, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. Insiders have sold 17,851 shares of company stock valued at $3,685,674 in the last quarter. Insiders own 0.25% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.